News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
289,515 Results
Type
Article (15357)
Company Profile (298)
Press Release (273856)
Multimedia
Podcasts (98)
Webinars (12)
Section
Business (80321)
Career Advice (172)
Deals (13461)
Drug Delivery (44)
Drug Development (50889)
Employer Resources (31)
FDA (5931)
Job Trends (5212)
News (145912)
Policy (10113)
Tag
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Genetown Standard (4)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (948)
Accelerated approval (29)
Adcomms (14)
Allergies (104)
Alliances (21860)
ALS (166)
Alzheimer's disease (1137)
Antibody-drug conjugate (ADC) (397)
Approvals (6221)
Artificial intelligence (365)
Autoimmune disease (253)
Automation (11)
Bankruptcy (105)
Best Places to Work (4580)
BIOSECURE Act (6)
Biosimilars (122)
Biotechnology (228)
Bladder cancer (121)
Brain cancer (58)
Breast cancer (425)
Cancer (4020)
Cardiovascular disease (293)
Career advice (161)
Career pathing (10)
CAR-T (276)
CDC (8)
Celiac Disease (1)
Cell therapy (730)
Cervical cancer (23)
Clinical research (44971)
Collaboration (1447)
Company closure (3)
Compensation (754)
Complete response letters (57)
COVID-19 (1135)
CRISPR (108)
C-suite (769)
Cystic fibrosis (120)
Data (5791)
Denatured (20)
Depression (115)
Dermatology (57)
Diabetes (316)
Diagnostics (1469)
Digital health (18)
Diversity (6)
Diversity, equity & inclusion (9)
Drug discovery (261)
Drug pricing (52)
Drug shortages (3)
Duchenne muscular dystrophy (275)
Earnings (32847)
Editorial (33)
Employer branding (4)
Employer resources (29)
Events (53638)
Executive appointments (698)
FDA (8119)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (17)
Frontotemporal dementia (31)
Funding (1198)
Gene editing (227)
Generative AI (34)
Gene therapy (605)
GLP-1 (562)
Government (1188)
Grass and pollen (3)
Guidances (175)
Healthcare (6764)
HIV (27)
Huntington's disease (51)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (89)
Immunology and inflammation (235)
Immuno-oncology (82)
Indications (130)
Infectious disease (1287)
Inflammatory bowel disease (183)
Inflation Reduction Act (10)
Influenza (55)
Intellectual property (203)
Interviews (18)
IPO (7372)
IRA (13)
Job creations (875)
Job search strategy (138)
JPM (41)
Kidney cancer (9)
Labor market (30)
Layoffs (253)
Leadership (14)
Legal (1408)
Liver cancer (46)
Longevity (24)
Lung cancer (537)
Lymphoma (299)
Machine learning (34)
Management (7)
Manufacturing (520)
MASH (161)
Medical device (2725)
Medtech (2746)
Mergers & acquisitions (6814)
Metabolic disorders (900)
mRNA (160)
Multiple sclerosis (124)
NASH (14)
Neurodegenerative disease (324)
Neuropsychiatric disorders (82)
Neuroscience (2305)
Neurotech (1)
NextGen: Class of 2026 (2063)
Non-profit (895)
Now hiring (39)
Obesity (399)
Opinion (142)
Ovarian cancer (187)
Pain (133)
Pancreatic cancer (231)
Parkinson's disease (300)
Partnered (12)
Patents (387)
Patient recruitment (503)
Peanut (49)
People (27320)
Pharmaceutical (42)
Pharmacy benefit managers (6)
Phase 1 (15947)
Phase 2 (20926)
Phase 3 (13194)
Pipeline (5933)
Policy (104)
Postmarket research (853)
Preclinical (6758)
Press Release (30)
Prostate cancer (199)
Psychedelics (58)
Radiopharmaceuticals (282)
Rare diseases (869)
Real estate (1469)
Recruiting (12)
Regulatory (10576)
Reports (20)
Research institute (987)
Resumes & cover letters (20)
Rett syndrome (35)
RNA editing (28)
RSV (24)
Schizophrenia (146)
Series A (235)
Series B (161)
Service/supplier (1)
Sickle cell disease (95)
Special edition (20)
Spinal muscular atrophy (125)
Sponsored (17)
Startups (2045)
State (1)
Stomach cancer (5)
Supply chain (38)
Tariffs (19)
The Weekly (76)
Vaccines (397)
Venture capital (88)
Weight loss (214)
Women's health (45)
Worklife (2)
Date
Today (69)
Last 7 days (441)
Last 30 days (1968)
Last 365 days (17885)
2026 (8352)
2025 (18101)
2024 (20558)
2023 (22443)
2022 (26880)
2021 (27884)
2020 (23433)
2019 (16325)
2018 (11799)
2017 (13794)
2016 (11913)
2015 (14424)
2014 (10456)
2013 (7567)
2012 (7607)
2011 (7701)
2010 (7485)
Location
Africa (158)
Alabama (72)
Alaska (2)
Arizona (82)
Arkansas (6)
Asia (18719)
Australia (3201)
California (8559)
Canada (2185)
China (1015)
Colorado (304)
Connecticut (323)
Delaware (294)
Europe (40244)
Florida (1105)
Georgia (252)
Hawaii (2)
Idaho (18)
Illinois (517)
India (46)
Indiana (199)
Iowa (8)
Japan (298)
Kansas (84)
Kentucky (11)
Louisiana (14)
Maine (12)
Maryland (885)
Massachusetts (6801)
Michigan (127)
Minnesota (309)
Mississippi (3)
Missouri (35)
Montana (17)
Nebraska (8)
Nevada (47)
New Hampshire (22)
New Jersey (1946)
New Mexico (13)
New York (2132)
North Carolina (1002)
North Dakota (7)
Northern California (4336)
Ohio (214)
Oklahoma (11)
Oregon (23)
Pennsylvania (1586)
Puerto Rico (11)
Rhode Island (27)
South America (220)
South Carolina (12)
Southern California (3430)
Tennessee (51)
Texas (1166)
United States (28326)
Utah (118)
Virginia (175)
Washington D.C. (37)
Washington State (706)
West Virginia (1)
Wisconsin (57)
289,515 Results for "sage therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Sage’s Search for Lifeline Ran Into Defiant Biogen CEO
After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was searching for a path forward at the end of December 2024. Biogen CEO Chris Viehbacher spied a possible deal, but the smaller company wasn’t interested.
July 3, 2025
·
3 min read
·
Annalee Armstrong
Layoffs
Sage Sacks Entire Staff After Supernus Buyout
As of Apr. 22, Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks after Maryland’s Supernus Pharmaceuticals acquired Sage for up to $795 million.
June 30, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
August 1, 2025
·
9 min read
Press Releases
RevMedica Announces Abstract Highlighting Real-Time, Actionable Insight Technology Accepted at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Annual Meeting
March 13, 2026
·
2 min read
Press Releases
Sage Therapeutics Announces Second Quarter 2025 Financial Results
July 30, 2025
·
16 min read
Neuroscience
Biogen Submits Offer to Buy Embattled Partner Sage
Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of Sage Therapeutics have fallen by more than 90%.
January 13, 2025
·
3 min read
·
Heather McKenzie
Layoffs
Sage Therapeutics Will Lay Off 33% of Employees, Including Over Half of R&D
As part of a strategic reorganization intended in part to support the ongoing launch of its postpartum depression drug, Sage Therapeutics is cutting more than 165 employees.
October 17, 2024
·
2 min read
·
Angela Gabriel
Legal
Sage Sues Partner Biogen After Unsolicited Takeover Offer
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital Markets.
January 21, 2025
·
2 min read
·
Tristan Manalac
Editorial
Embattled Sage Dealt Deeper Blow With Huntington’s Failure
Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts to question the biotech’s future profitability.
November 25, 2024
·
4 min read
·
Heather McKenzie
Press Releases
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
June 16, 2025
·
17 min read
1 of 28,952
Next
